Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors
Open Access
- 11 August 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (16) , 5774
Abstract
Over the last decade, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several cancer types. ICIs work through the blockage of immune inhibitory signals, while increasing the T-cell specific immune antitumoral response. However, due to the fact that ICIs’ mechanism of action is not tissue antigen-specific and not limited to the tumor microenvironment, the use of cancer immunotherapy can produce a broad range of immune-related adverse events (irAEs). Neurological immune-related adverse events (NirAEs) are rare (the overall incidence varies between 1% to 6%), and these adverse events mainly concern the peripheral nervous system, rather than the central nervous system. Due to their potential severity, which could cause interruptions to cancer treatment, NirAEs are of particular clinical importance. Currently, the pathogenesis of these complications is not completely understood, although T-cells seem to play a principal role. Nevertheless, the development of NirAEs is likely to be a multifactorial and complex process. This conclusion can be extracted from the wide range of neurological auto-inflammatory and autoimmune disorders triggered or exacerbated by ICIs, and the extensive variability of the limited histological findings reported. The aim of this review is to summarize the potential immune-driven pathological mechanisms of NirAEs.Keywords
This publication has 65 references indexed in Scilit:
- Immunogenic Cell Death in Cancer TherapyAnnual Review of Immunology, 2013
- PD-1 is a novel regulator of human B-cell activationInternational Immunology, 2012
- Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer PatientsThe Journal of Immunology, 2012
- Exome sequencing identifies GRIN2A as frequently mutated in melanomaNature Genetics, 2011
- Mechanisms of toleranceImmunological Reviews, 2011
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Mechanisms of Foxp3+ T Regulatory Cell-Mediated SuppressionImmunity, 2009
- Immune circuitry in the peripheral nervous systemCurrent Opinion in Neurology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Paraneoplastic Syndromes Involving the Nervous SystemNew England Journal of Medicine, 2003